CD274 and esophageal squamous cell carcinoma: Indoleamine 2,3-dioxygenase 1 and PD-L1 co-expression could predict poor pathologic response and high risk of recurrence in ESCC after neoadjuvant CRT, indicating a subset of patients who may benefit from CRT combined with immunotherapy.